A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Clinical Study of the Treatment of Disitamab Vedotin(RC48) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Expressing HER2
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Dong sheng Zhang, PhD
- Phone Number: 86-020-87342479
- Email: zhangdsh@sysucc.org.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Age: 18 (inclusive) or above, regardless of gender.
- 2. histologically or cytologically confirmed patients with locally advanced or metastatic pancreatic cancer who cannot undergo radical surgery
- 3. HER2 expressing(Immunohistochemical IHC 1+,2+ or 3+)
- 4. Number of treatment lines: Cohort 1: Prior first-line gemcitabine-free regimen or intolerant to gemcitabine-containing regimen; Cohort 2: Previous treatment with second-line standard or intolerance
- 5. Patients who have previously received neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy or chemoradiotherapy for the purpose of curing non-metastatic disease must have a disease-free interval of 6 months from the last chemotherapy and/or radiotherapy to the random date
- 6. There is at least one measurable lesion that meets the definition of the RECIST 1.1 standard at baseline.
- 7. ECOG fitness status score: 0 or 1 point.
- 8. Estimated survival time ≥ 3 months.
- 9. Adequate organ function.
- 10. Male and female participants are eligible to participate if they agree to the contraception use as per study protocol.
- 11. Voluntary agreement to provide written informed consent.
Exclusion Criteria:
- 1. Central nervous system metastasis or meningeal metastasis with clinical symptoms.
- 2. Have a history of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
- 3. Active hepatitis B (hepatitis B virus titer>1000 copies/ml or 200 IU/ml); Hepatitis C virus and syphilis infection.
- 4. Have undergone major organ surgery (excluding puncture biopsy) or have experienced significant trauma within 3 weeks before the first use of the study drug.
- 5. Known hypersensitivity or intolerance to any component of the study protocol drug or its excipients.
- 6. Strong inducers and inhibitors of P-gp, a strong or moderate inducer of CYP3A4, used within 14 days prior to the first use of the study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Disitamab Vedotin combined with Gemcitabine,2L
Disitamab Vedotin 2.5 mg/kg,iv,Q3W; Gemcitabine 1g/m2,iv,d1, d8 Q3W; Disitamab Vedotin+Gemcitabine is used as second-line treatment for HER2-expressive patients who have failed first-line gemcitabine-free regimen or are intolerant to gemcitabine-containing regimen.
|
Gemcitabine
Disitamab Vedotin
Other Names:
|
|
Experimental: Disitamab Vedotin,3L
Disitamab Vedotin 2.5 mg/kg,iv,Q3W; Disitamab Vedotin in HER2-expressive patients who have failed at second-line standard treatment or are intolerant
|
Disitamab Vedotin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Object Response Rate, ORR
Time Frame: up to 12 months
|
Defined as the percentage of participants with a complete response (CR) or partial response (PR)
|
up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events (AE)
Time Frame: up to 12 months
|
NCI-CTCAE v5.0
|
up to 12 months
|
|
Disease Control Rate, DCR
Time Frame: up to 12 months
|
Defined as the proportion of participants who have a complete response (CR), partial response (PR) or standard disease (SD) as assessed by investigator according to RECIST 1.1
|
up to 12 months
|
|
Progress Free Survival, PFS
Time Frame: up to 12 months
|
Defined as time from randomization until progression per RECIST 1.1 as assessed by investigator, or death due to any cause.
|
up to 12 months
|
|
Over Survival, OS
Time Frame: up to 12 months
|
Defined as time from randomization until the date of death due to any cause.
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dong sheng Zhang, PhD, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Immunoconjugates
- Gemcitabine
- Disitamab vedotin
Other Study ID Numbers
Other Study ID Numbers
- M01-RC48
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.